Delivery Order SPE2DB22D2007-SPE2DB25FJ4YF
- Not listed
- The Defense Logistics Agency awarded a $3,465.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of August 15, 2025. This non-set-aside competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order is to be fulfilled at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,465.10 on August 19, 2025, for HYPERRAB 300 Unit/mL vials. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania, and an ultimate completion date of September 10, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support...
- The Defense Logistics Agency awarded a $17,908 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 1, 2025, for the supply of HYPERRAB 300 Unit/ML vials (5ML units). This is a non-set-aside competitive award with an ultimate completion date of September 22, 2025, and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for HYPERRAB 300 Unit/mL vials with a ceiling value of $2,425.57. The contract is a firm fixed price delivery order with an ultimate completion date of September 29, 2025. This award is a non-set-aside competitive procurement issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of October 3, 2025. This firm fixed-price delivery order, awarded on September 14, 2025, represents a non-competitive set-aside procurement and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $17,908 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Hyperrab 300 Unit/mL vials (5mL). This competitively awarded, non-set-aside contract reflects firm fixed pricing and is scheduled for completion by June 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems....
- The Defense Logistics Agency awarded a delivery order valued at $17,908 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product. This firm fixed-price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4YFDelivery Order
The Defense Logistics Agency awarded a $3,465.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/ML vials, with an ultimate completion date of October 6, 2025. This non-set-aside contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime contract vehicle designated SPE2DX that runs through December 2026 and serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has demonstrated substantial capability in federal medical procurement through competitive awards across the DLA's Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This particular delivery order for rabies immunoglobulin (HYPERRAB) represents a routine fulfillment under the broader prime vendor contract that enables flexible pharmaceutical sourcing to meet military medical requirements across multiple therapeutic domains and global locations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 9/15/25 |